Dermatology and Aesthetic Medicine: Industry Report

Summary

This report covers dermatology and aesthetic medicine. It uses a global frame for aesthetic procedure volumes and a United States frame for workforce and access evidence ⁹¹⁰¹¹¹. Latest available data show high aesthetic procedure demand, with nearly 38 million procedures recorded worldwide ⁹. Access is the most consistent constraint in the sources. Dermatologist supply is unevenly distributed, nonmetropolitan areas are described as under-supplied, and new patient waits in several studies run for weeks ²¹⁵⁸¹¹. A workforce projection shows supply rising but still short of demand under an improved access scenario ¹. The main risks are access delay, uneven geographic distribution, and missing verified data on cost, safety and regulation. The outlook favors staffing models that add clinical capacity, but the pack contains only one documented example of this approach ⁷.

Key findings

1. 1

   Projected US supply grows, but a shortfall remains under an improved access scenario

   A peer-reviewed projection estimates total dermatology workforce supply rising 12.45% over its projection period, yet under the improved access scenario supply lags demand by 28% in the stated year ¹. These are forecasts that depend on the study's assumptions.

   Confidence: Medium
2. 2

   Rural and nonmetropolitan patients face thinner dermatology coverage

   Peer-reviewed geospatial work describes a pronounced urban over rural disparity in dermatologist distribution, and links limited resources to higher risk of advanced skin cancers and poorer outcomes ². A separate study concludes the workforce is inadequate in nonmetropolitan areas ¹.

   Confidence: High
3. 3

   New patient waits remain long in several US measures

   Reported mean waits include 33 calendar days in an earlier national comparison ⁴, 56 calendar days in an Ohio survey of 269 dermatologists with a median of 41 days ⁸, and an average of 32.3 days in a cited access study that reports a 46% increase ¹¹. More than 60% of surveyed dermatologists exceeded benchmark waits of 3 weeks for new patients ⁵. The sources use different years and methods, so the figures are not directly comparable.

   Confidence: Medium
4. 4

   A staffing redesign cut waits sharply at one safety-net clinic

   A Dallas, Texas safety-net dermatology clinic reduced new patient waits from 377 days to 48 days after targeted staffing and scheduling changes, and a higher nurse-to-resident ratio cut waits by 31% in the first year ⁷. This is a single-site, observational result without a comparator group.

   Confidence: High
5. 5

   Aesthetic procedure volumes are large, but revenue data are unreliable

   ISAPS-based figures cited by market research record about 7.8 million botulinum toxin procedures and nearly 38 million aesthetic procedures globally ⁹. Market revenue estimates diverge widely across publishers, so no single reliable market size is verified ¹⁰.

   Confidence: Medium
6. 6

   Cost, safety oversight and digital health are not verified in this pack

   The pack has no primary regulator or payer sources on injector oversight, adverse event rates, insurance coverage for cosmetic versus medical dermatology, or telehealth adoption. Conclusions in these areas would be unsupported.

   Confidence: Qualitative

1Industry definition and scope

This report treats dermatology as the medical and surgical care of skin, hair and nails, and aesthetic medicine as procedures aimed mainly at appearance. Aesthetic procedures include non-surgical treatments such as botulinum toxin and hyaluronic acid, as well as surgical procedures ⁹. The two areas overlap in practice. Among typical US dermatologists in an older survey, 63% of direct patient care time went to medical dermatology and 10% to cosmetic dermatology ⁴.

The geographic scope is global for aesthetic procedure volumes, which come from ISAPS survey data as cited by market research ⁹¹⁰. Workforce, distribution and access evidence is limited to the United States ¹²¹¹. The reporting period is the latest available data. Many workforce studies are older, and their years differ, so cross-study comparisons are approximate.

Wait time in these studies usually means the number of calendar days until a new patient appointment, reported as a mean or median. Segments covered are medical dermatology, cosmetic dermatology, and aesthetic procedures delivered in clinics and aesthetic centers ¹⁰. This report does not address individual clinical decisions.

Scope was set by the pack. Where a source measures a different population or period, the report says so.

2Market size, structure and value chain

The pack supports volume figures better than revenue figures. ISAPS-based data cited by market research record nearly 38 million aesthetic procedures worldwide in the latest available data, with botulinum toxin and hyaluronic acid as the leading non-surgical procedures ⁹. A second market research report cites 17.42 million surgical and 20.54 million non-surgical procedures for the same survey ¹⁰. Those two totals sum to nearly 38 million. This is the writer's arithmetic, and both reports rely on the same survey, so they do not confirm each other independently.

Market revenue is not verified. Estimates from market research publishers diverge widely, so no single reliable market size is supported by the pack ¹⁰. This report therefore does not state a market value or growth rate.

Clinics and aesthetic centers held a 48.1% share of end use in the latest available data ¹⁰. The pack does not give the share for hospitals, physician offices or other settings. The value chain is also incomplete: it does not name toxin or filler manufacturers, distributors or device suppliers, and it does not describe their pricing.

Revenue models are not documented in the pack. A general statement that many aesthetic botulinum toxin procedures are paid out of pocket is not verified against a primary source. Key stakeholders in the evidence are dermatologists, patients seeking aesthetic care, clinics and aesthetic centers, and the survey and market research bodies that publish the figures.

• Aesthetic procedures recorded worldwide 38million procedures Observed Global, Latest available data [9]

Volume figures are reported as the sources give them. Revenue is excluded because the pack shows no reliable verified value.

3Customers, demand and adoption

Demand for dermatology appointments is high relative to available capacity. A mean new patient wait of 36 calendar days was recorded in an earlier national survey, with state means from 9 to 120 days ³. A later comparison found the mean had fallen slightly to 33 days ⁴. A recent Ohio survey of 269 practicing dermatologists found a mean wait for the next available appointment of 56 days and a median of 41 days ⁸. A cited access study reports an average wait of 32.3 days, up 46% since an earlier study ¹¹. More than 60% of surveyed dermatologists exceeded benchmark waits of 3 weeks for new patients and 2 weeks for return visits ⁵.

The table below compares the reported figures. The studies differ in year, population and method, so the table shows the range rather than a trend.

Cosmetic demand also competes for the same appointment slots. Median waits for cosmetic botulinum toxin appointments ranged from 6.0 to 32.5 days across the sampled communities, compared with 26 days for an appointment about a changing mole ⁶. This is the writer's interpretation: appointments for appearance concerns and for possible skin cancer can share a queue, and the pack does not show how clinics triage them.

Dermatologists in higher population density areas had shorter new patient waits and were more likely to include cosmetic dermatology ⁵. Purchasing criteria, patient satisfaction and out-of-pocket spending are not measured in the pack, so this report cannot describe how patients choose providers.

• Average wait to see a dermatologist 32.3days Observed United States, Cited access study, latest available data [11]

Comparisons rely on secondary reporting for S8 and S11, and the underlying study years are not confirmed.

4Competitive landscape and key players

The pack does not contain company revenue, market share or product comparisons for toxin, filler or device suppliers, and it names no commercial aesthetic chain. Competitive comparison is therefore limited to provider types. Comparable company-level examples were limited in the source pack.

Provider types visible in the evidence are private dermatology practices, academic and hospital settings, safety-net clinics, and clinics and aesthetic centers. Clinics and aesthetic centers held 48.1% of end-use share in the latest available data ¹⁰. Typical dermatologists in an older survey spent most direct care time on medical dermatology, which suggests that cosmetic services are often an add-on rather than the whole practice ⁴.

Business models differ. Cosmetic services are generally priced for the patient, while medical dermatology depends on payer rules that the pack does not verify. A safety-net clinic in Dallas, Texas, serves a patient population with limited ability to pay, and its waits were reduced through staffing changes rather than a new revenue model ⁷.

Competitive pressure is geographic. Dermatologists in denser areas had shorter waits and offered more cosmetic care ⁵. Practices in rural areas therefore face both a supply gap and less competition from cosmetic providers ²⁵. This is the writer's interpretation, based on two studies that do not measure competition directly.

Concentration in the market cannot be measured from the pack. No share figures are given for individual providers or suppliers.

• Share of aesthetic end use held by clinics and aesthetic centers 48.1percent Observed Global, Latest available data [10]

No company names are attributed beyond the sources. The comparison is kept to categories the pack supports.

5Technology, operations and workforce

The clearest workforce evidence is a peer-reviewed projection for the United States. It estimates that total dermatology workforce supply rises by 12.45% over the projection period ¹. Under the improved access scenario, supply is inadequate for demand in every projected year, lagging by 28% in the stated year ¹. The study concludes the dermatology physician workforce is inadequate in nonmetropolitan areas ¹. These are forecasts, and the assumptions behind them are not reproduced in the pack.

Operations matter as much as headcount. A Dallas safety-net clinic cut new patient waits from 377 days to 48 days after targeted staffing and scheduling changes ⁷. Increasing the nurse-to-resident ratio and reorganizing support schedules cut waits by 31% in the first year ⁷. A reporting of an Ohio study frames physician extenders as a way to reduce waits ⁸, but the pack does not give the study's own effect size.

Non-physician clinicians appear in the evidence only in qualitative terms. No current share figure is verified for physician assistants or nurse practitioners in dermatology.

Technology adoption is not verified. The pack has no primary source on digital health, telehealth, imaging or artificial intelligence in dermatology, so this report cannot assess how these tools change capacity or quality.

Skills and talent supply are reflected only indirectly through the workforce projection. The pack gives no data on training pipelines, retention or regional recruitment.

• Projected increase in total dermatology workforce supply 12.45percent Forecast United States, Projection period stated in the study [1]
• Projected supply shortfall under improved access scenario 28percent Forecast United States, Projected year stated in the study [1]

Forecasts are reported as forecasts. Operational results come from one clinic and are not generalized.

6Regulation, standards, risk and sustainability

Jurisdiction matters. The regulatory evidence in this pack relates to the United States only where workforce and access sources apply ¹²¹¹. The pack contains no binding rules, proposed rules or voluntary guidance from any regulator or standards body on aesthetic procedures, injector qualifications, device approval or advertising. This report therefore does not state what the law requires in any market.

Safety and quality evidence is limited. The pack has no verified adverse event rates, no data on non-physician injector oversight, and no outcome measures beyond access. Waits, distribution and workforce are the only quality-adjacent measures available ¹⁵⁷.

Patient risk is documented in one area. Patients in regions with limited dermatological resources face heightened risk of advanced skin cancers and poorer outcomes ². The pack does not quantify this risk, so it should be read as a qualitative finding.

Privacy and equity are only partly covered. The sources in this report are aggregate figures, so no individual patient data are used. Equity beyond geography, including race, income and insurance status, is not verified in this pack.

Environmental and social sustainability of aesthetic supply chains is not covered by any source in the pack. Operational risks visible in the evidence include staffing shortages, long waits and geographic gaps ¹⁸¹¹.

This section describes evidence, not legal compliance. Readers who need regulatory conclusions should consult primary jurisdictional sources.

7Challenges, opportunities and case examples

The main constraint is access. Waits in the sources are long, and capacity is unevenly distributed ¹²⁵⁸¹¹. Affordability is a second constraint, but the pack does not verify its scale. The third is evidence depth: many key indicators are single studies, older surveys or secondary reports.

The Dallas case is the clearest example of an operational fix. A safety-net dermatology clinic in Dallas, Texas, reduced new patient waits from 377 days to 48 days ⁷. The study reports a 31% cut in waits in the first year after increasing the nurse-to-resident ratio ⁷. The result is observational, from one site, and the pack reports no comparison clinic. It is an example of what changed, not proof that the same approach will work elsewhere.

The second example is market-level. ISAPS-based data show that aesthetic demand is large and globally distributed, with nearly 38 million procedures recorded ⁹. This shows where demand exists, but it does not show whether patients can access care or how much they pay.

Opportunities follow from these gaps. Staffing redesign is a documented, low-cost lever in one case ⁷. Expanding capacity in nonmetropolitan areas is a need identified in the workforce evidence ¹². Better public data on cost, safety and digital access would support decisions in both medical and aesthetic care, but the pack does not provide such data.

Limited comparable examples are available in the pack. Ohio and national wait studies are surveys rather than provider cases ⁵⁸.

Case examples are limited to two sources and one clinic. Market-level evidence does not substitute for provider-level evidence.

8Outlook and strategic implications

In the near term, the evidence points to continued pressure on access. Waits reported in recent surveys are long, and a US projection shows supply still short of demand under an improved access scenario ¹⁸¹¹. Supply growth alone is unlikely to close gaps quickly on the projection's own terms ¹. This is the writer's interpretation.

In the medium term, aesthetic demand appears to be growing, based on recorded procedure volumes ⁹¹⁰. The pack does not provide growth rates for procedures or revenue, so the strength and duration of that growth cannot be stated.

Practical implications differ by stakeholder. Providers can test staffing and scheduling changes with measurement, as the Dallas example did ⁷. Payers and public health bodies need verified data on cost, coverage and access before setting rules, and the pack does not supply it. Manufacturers and market analysts should treat revenue estimates with caution, since they diverge widely ¹⁰. Researchers should prioritize current, harmonized wait-time and workforce surveys across states and countries.

Outlook statements are interpretations of the evidence. They are not forecasts from the sources except where marked as forecast.

9Conclusion

Dermatology and aesthetic medicine show strong demand and persistent access constraints. The most defensible takeaways are that appointment waits are long in several US measures, rural capacity is thin, and staffing redesign can reduce waits, as one safety-net clinic showed ¹²⁷⁸. Revenue size, cost, safety oversight and digital adoption remain unverified.

How this was built

Sources

1. 1

   Dermatology workforce projections in the United States

   Balboul S, Gronbeck C, Feng H (published in Archives of Dermatological Research, Springer) Peer-reviewed

   link.springer.com
2. 2

   Geospatial analysis of dermatologist distribution and access among US seniors

   Afvari S, Collet DA, Goyal A, Aifuwa E, LaChance AH, Safai B (Journal of Dermatology Investigations / PMC) Peer-reviewed

   ncbi.nlm.nih.gov
3. 3

   The dermatology workforce shortage

   Resneck J Jr, Kimball AB (Journal of the American Academy of Dermatology, via PubMed) Peer-reviewed

   pubmed.ncbi.nlm.nih.gov
4. 4

   The US dermatology workforce: a specialty remains in shortage

   Kimball AB, Resneck JS Jr (Journal of the American Academy of Dermatology) Peer-reviewed

   research.bidmc.org
5. 5

   Waiting Times to See a Dermatologist Are Perceived as Too Long by Dermatologists: Implications for the Dermatology Workforce

   JAMA Dermatology Peer-reviewed

   jamanetwork.com
6. 6

   Short wait times for patients seeking cosmetic botulinum toxin appointments with dermatologists

   Resneck J, Lipton S, Pletcher M (Journal of the American Academy of Dermatology) Peer-reviewed

   jaad.org
7. 7

   Reducing outpatient dermatology clinic wait times in a safety net health system in Dallas, Texas

   American Academy of Dermatology (Journal of the American Academy of Dermatology) Peer-reviewed

   jaad.org
8. 8

   Physician Extenders Reduce Wait Times for Dermatology Appointments, Study Finds (JAMA Dermatology study reported by AJMC)

   American Journal of Managed Care (reporting on JAMA Dermatology study) News report

   ajmc.com
9. 9

   Aesthetic Medicine Market Size & Share (ISAPS survey data cited)

   Global Market Insights (market research citing International Society of Aesthetic Plastic Surgery) Market research

   gminsights.com
10. 10

    Aesthetic Medicine Market Size & Share Report (ISAPS data cited)

    Grand View Research (market research citing ISAPS) Market research

    grandviewresearch.com
11. 11

    Getting to the dermatologist is only half the battle for biologic patients

    Managed Healthcare Executive (news report summarizing a US dermatology access study) News report

    managedhealthcareexecutive.com